Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy
Open accessThe DOI matches its Crossref record; 75 of the 79 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cyclin-dependent kinases (CDKs) regulate cell proliferation and coordinate the cell cycle checkpoint response to DNA damage. Although inhibitors with varying selectivity to specific CDK family members have been developed, selective CDK4/6 inhibitors have emerged as the most attractive antineoplastic agents because of the importance of CDK4/6 activity in regulating cell proliferation and the toxic effects associated with inhibition of other CDKs (eg, CDK1 and CDK2). METHODS: FVB/N wild-type mice (n = 13) were used to evaluate carboplatin-induced myelosuppression in bone marrow by complete blood cell counts after treatment with the CDK4/6 inhibitor PD0332991. Genetically engineered murine models of retinoblastoma (Rb)-competent (MMTV-c-neu) and Rb-incompetent (C3-TAg) breast cancer (n = 16 MMTV-c-neu mice in the carboplatin plus vehicle control group, n = 17 MMTV-c-neu mice in the carboplatin plus PD0332991 group, n = 17 C3-TAg mice in the carboplatin plus vehicle control group, and n = 14 C3-TAg mice in the carboplatin plus PD0332991 group) were used to investigate the antitumor activity of PD0332991 alone or in combination with chemotherapy. All statistical tests were two-sided. RESULTS: Coadministration of PD0332991 with carboplatin compared with carboplatin alone in FVB/N wild-type mice increased hematocrit (51.2% vs 33.5%, difference = 17.7%, 95% confidence interval [CI] = -26.7% to -8.6%, P < .001), platelet counts (1321 vs 758.5 thousand cells per μL, difference = 562.5 thousand cells per μL, 95% CI = -902.8 to -222.6, P = .002), myeloid cells (granulocytes and monocytes; 3.1 vs 1.6 thousand cells per μL, difference = 1.5 thousand cells per μL, 95% CI = -2.23 to -0.67, P < .001), and lymphocytes (7.9 vs 5.4 thousand cells per μL, difference = 2.5 thousand cells per μL, 95% CI = -4.75 to -0.18, P = .02). Daily administration of PD0332991 exhibited antitumor activity in MMTV-c-neu mice as a single agent. However, the combination of carboplatin plus PD0332991 decreased antitumor activity compared with carboplatin alone in Rb-competent mice (mean percent change in tumor volume at day 21 = -52.6% vs 3.7% for carboplatin and carboplatin plus PD0332991, respectively, difference = 56.3%, 95% CI = -109.0% to -3.6%, P = .04). In contrast, Rb-deficient tumors in C3-Tag mice were resistant to PD0332991, and coadministration of PD0332991 plus carboplatin had no effect on in vivo tumor growth (mean percent change in tumor volume at day 21 = 118.8% and 109.1% for carboplatin and carboplatin plus PD0332991, respectively, difference = 9.7%, 95% CI = -183.5% to 202.9%, P = .92). Finally, in tumor-bearing mice, coadministration of PD0332991 with carboplatin provided statistically significant protection of platelets (P = .04). CONCLUSION: We believe that the present data support a possible role for CDK4/6 inhibitors in a majority of patients with advanced cancer: to either inhibit tumor growth in CDK4/6-dependent tumors or ameliorate the dose-limiting toxicities of chemotherapy in CDK4/6-indepdendent tumors. Our data also suggest CDK4/6 inhibitors should not be combined with DNA-damaging therapies, such as carboplatin, to treat tumors that require CDK4/6 activity for proliferation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in a mouse RB-competent MMTV-HER2-driven breast cancer model, the anti-tumor activity of carboplatin was compromised by palbociclib administration, whereas in an RB-deficient model, palbociclib co-administration protected against carboplatin-induced hematologic toxicity (129).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [129]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Self-citationCell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 2×
“There are four proliferative CDKs: CDK1, which predominantly regulates the transition from G2 to M phase, and CDK2/4/6, which regulate the transition from G1 to S phase (1,2).”
BackgroundMethodGiaccone, G., Herbst, R. S., Manegold, C., Scagliotti, G., Rosell, R., Miller, V., Natale, R. B., Schiller, J. H., von Pawel, J., Pluzanska, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.001 · Cited by 1,716
Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V., Manegold, C., Scagliotti, G., Rosell, R., Oliff, I., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,707
Herbst, R. S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B. E., Sandler, A., Kris, M. G., Tran, H. T., Klein, P., Li, X., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.840 · Cited by 1,490
To cycle or not to cycle: a critical decision in cancer
Malumbres, M., & Barbacid, M. (2001) · Nature Reviews Cancer · doi:10.1038/35106065 · Cited by 1,468
Eberhard, D. A., Johnson, B. E., Amler, L. C., Goddard, A. D., Heldens, S. L., Herbst, R. S., Ince, W. L., Jänne, P. A., Januario, T., Johnson, D. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.857 · Cited by 1,461
Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Herschkowitz, J. I., Simin, K., Weigman, V. J., Mikaelian, I., Usary, J., Hu, Z., Rasmussen, K. E., Jones, L. P., Assefnia, S., Chandrasekharan, S., et al. (2007) · Genome Biology · doi:10.1186/gb-2007-8-5-r76 · Cited by 1,285
Self-citationHenke, M., Laszig, R., Rübe, C., Schäfer, U., Haase, K.-D., Schilcher, B., Mose, S., Beer, K. T., Burger, U., Dougherty, C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14567-9 · Cited by 1,250
Cited by
Items 101–200 of 274
Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors
Gomatou, G., Trontzas, I. P., Ioannou, S., Drizou, M., Syrigos, N. K., & Kotteas, E. A. (2021) · Molecular Biology Reports · doi:10.1007/s11033-020-06100-3 · Cited by 47
Cdk4 and Nek2 Signal Binucleation and Centrosome Amplification in a Her2+ Breast Cancer Model
Pitner, M. K., & Saavedra, H. I. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065971 · Cited by 47
Iriyama, N., Hino, H., Moriya, S., Hiramoto, M., Hatta, Y., Takei, M., & Miyazawa, K. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1376741 · Cited by 47
Lung tumor growth-promoting function of peroxiredoxin 6
Jo, M., Yun, H., Park, K., Park, M. H., Kim, T. M., Pak, J. H., Lee, S. J., Moon, D. C., Park, C., Song, S., et al. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.04.032 · Cited by 46
Cyclin-dependent kinase pathways as targets for women's cancer treatment
Konecny, G. E. (2015) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000243 · Cited by 46
The emerging role of CDK4/6i in HER2-positive breast cancer
O'Sullivan, C. C., Suman, V. J., & Goetz, M. P. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919887665 · Cited by 46
Costa, R. L. B., Carneiro, B. A., Wainwright, D. A., Santa-Maria, C. A., Kumthekar, P., Chae, Y. K., Gradishar, W. J., Cristofanilli, M., & Giles, F. J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw532 · Cited by 44
Mutation matters in precision medicine: A future to believe in
Dey, N., Williams, C. B., Leyland-Jones, B. R., & De, P. K. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.03.002 · Cited by 43
Palbociclib has antitumour effects on Pten‐deficient endometrial neoplasias
Santamaría, M. D., Mirantes, C., Eritja, N., Felip, I., Navaridas, R., Gatius, S., Santacana, M., Colás, E., Moiola, C. P., Schoenenberger-Arnaiz, J. A., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4896 · Cited by 43
Overview of Genetically Engineered Mouse Models of Distinct Breast Cancer Subtypes
Usary, J., Darr, D. B., Pfefferle, A. D., & Perou, C. M. (2016) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph1438s72 · Cited by 43
Self-citationAnti-tumor effect of CDK inhibitors on CDKN2A-defective squamous cell lung cancer cells
Jeong, E.-H., Lee, T., Ko, Y. J., Kim, S. Y., Kim, H.-R., Kim, H., & Kim, C. H. (2018) · Cellular Oncology · doi:10.1007/s13402-018-0404-6 · Cited by 42
Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment
Parylo, S., Vennepureddy, A., Dhar, V., Patibandla, P., & Sokoloff, A. (2018) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155218770904 · Cited by 42
Silencing CDK4 radiosensitizes breast cancer cells by promoting apoptosis
Hagen, K. R., Zeng, X., Lee, M.-Y., Kahn, S., Pitner, M. K., Zaky, S. S., Liu, Y., O’Regan, R. M., Deng, X., & Saavedra, H. I. (2013) · Cell Division · doi:10.1186/1747-1028-8-10 · Cited by 42
Kamdje, A. H. N., Etet, P. F. S., Vecchio, L., Tagne, R. S., Amvene, J. M., Muller, J.-M., Krampera, M., & Lukong, K. E. (2014) · World Journal of Clinical Cases · doi:10.12998/wjcc.v2.i12.769 · Cited by 41
Dall’Acqua, A., Bartoletti, M., Masoudi-Khoram, N., Sorio, R., Puglisi, F., Belletti, B., & Baldassarre, G. (2021) · Cancers · doi:10.3390/cancers13123035 · Cited by 41
Lee, C., Oh, P., Xu, E. S., Ma, Y., Kim, Y., Daniel, A. R., & Kirsch, D. G. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.07.192 · Cited by 41
Targeting CDK4/6 pathways and beyond in breast cancer
Ribnikar, D., Volovăț, S. R., & Cardoso, F. (2018) · The Breast · doi:10.1016/j.breast.2018.10.001 · Cited by 40
CDK4/6 Inhibitor PD0332991 in Glioblastoma Treatment: Does It Have a Future?
Schröder, L. B. W., & McDonald, K. L. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00259 · Cited by 41
Knudsen, E. S., Shapiro, G. I., & Keyomarsi, K. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_281085 · Cited by 39
Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy
Migliaccio, I., Leo, A. D., & Malorni, L. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000129 · Cited by 38
Perumal, D., Kuo, P.-Y., Leshchenko, V. V., Jiang, Z., Divakar, S. K. A., Cho, H. J., Chari, A., Brody, J., Reddy, M. V. R., Zhang, W., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2934 · Cited by 37
Yousuf, M., Alam, M., Shamsi, A., Κhan, P., Hasan, G. M., Haque, Q. M. R., & Hassan, M. I. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.07.156 · Cited by 37
Pfefferle, A. D., Agrawal, Y., Koboldt, D. C., Kanchi, K., Herschkowitz, J. I., Mardis, E. R., Rosen, J. M., & Perou, C. M. (2016) · Disease Models & Mechanisms · doi:10.1242/dmm.025239 · Cited by 36
Self-citationSpring, L. M., Clark, S. L., Li, T., Goel, S., Tayob, N., Viscosi, E., Abraham, E., Juric, D., Isakoff, S. J., Mayer, E. L., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00311-y · Cited by 36
Preclinical and clinical development of palbociclib and future perspectives
de Dueñas, E. M., Gavilá-Gregori, J., Olmos-Antón, S., Santaballa, A., Lluch-Hernández, A., Domínguez, E. E., Rivero-Silva, M., & Llombart‐Cussac, A. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-1850-3 · Cited by 36
Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment Opportunity
Koirala, N., Dey, N., Aske, J. C., & De, P. K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126547 · Cited by 36
Advances in Rodent Models for Breast Cancer Formation, Progression, and Therapeutic Testing
Liu, C., Wu, P., Zhang, A., & Mao, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.593337 · Cited by 36
O'Sullivan, C. C. (2015) · International Journal of Cancer and Clinical Research · doi:10.23937/2378-3419/2/4/1029 · Cited by 35
New Approaches in Targeted Therapy for Medulloblastoma in Children
MAIER, H., Dalianis, T., & Kostopoulou, O. N. (2021) · Anticancer Research · doi:10.21873/anticanres.14936 · Cited by 34
Li, C., Qi, L., Bellail, A. C., Hao, C., & Liu, T. (2014) · Oncology Letters · doi:10.3892/ol.2014.1957 · Cited by 33
Pfefferle, A. D., Spike, B. T., Wahl, G., & Perou, C. M. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3262-6 · Cited by 32
Self-citationMinePath: Mining for Phenotype Differential Sub-paths in Molecular Pathways
Koumakis, L., Kanterakis, A., Kartsaki, E., Chatzimina, M., Zervakis, M., Tsiknakis, M., Vassou, D., Kafetzopoulos, D., Marias, K., Moustakis, V. S., et al. (2016) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005187 · Cited by 32
Emerging targets for radioprotection and radiosensitization in radiotherapy
Kumar, S., Singh, R. K., & Meena, R. (2016) · Tumor Biology · doi:10.1007/s13277-016-5117-8 · Cited by 31
CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma
Salvador-Barberó, B., Álvarez‐Fernández, M., Zapatero‐Solana, E., Bakkali, A. E., Menéndez, M. D. C., Lopez-Casas, P. P., Domenico, T. D., Xie, T., VanArsdale, T. L., Shields, D. J., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.09.012 · Cited by 31
Ikeda, Y., Oda, K., Ishihara, H., Wada‐Hiraike, O., Miyasaka, A., Kashiyama, T., Inaba, K., Fukuda, T., Sone, K., Matsumoto, Y., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.369 · Cited by 31
Prada, E. T. A., Nölting, S., Spoettl, G., Maurer, J., & Auernhammer, C. J. (2017) · Neuroendocrinology · doi:10.1159/000463386 · Cited by 29
The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer
Gomes, I., Abreu, C., Costa, L., & Casimiro, S. (2023) · Cancers · doi:10.3390/cancers15194835 · Cited by 27
Jin, D., Tran, N., Thomas, N. J., & Tran, D. D. (2019) · PLoS ONE · doi:10.1371/journal.pone.0223555 · Cited by 27
Bouclier, C., Simon, M., Laconde, G., Pellerano, M., Diot, S., Lantuéjoul, S., Busser, B., Vanwonterghem, L., Vollaire, J., Josserand, V., et al. (2020) · Theranostics · doi:10.7150/thno.40971 · Cited by 27
Synchronization of human retinal pigment epithelial-1 cells in mitosis
Scott, S. J., Suvarna, K., & D’Avino, P. P. (2020) · Journal of Cell Science · doi:10.1242/jcs.247940 · Cited by 26
Zou, J., Wu, K., Lin, C., & Jie, Z. (2019) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00405.2018 · Cited by 25
The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines
Lopes-Ventura, S., Pojo, M., Matias, A. T., Moura, M. M., Marques, I. J., Leite, V. A. P. H., & Cavaco, B. M. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0947-4 · Cited by 25
Çetin, B., Wabl, C. A., & Gümüşay, Ö. (2022) · Future Oncology · doi:10.2217/fon-2021-0842 · Cited by 25
A novel targeted therapy in breast cancer: cyclin dependent kinase inhibitors.
Akın, S., Babacan, T., Sarici, F., & Altundağ, K. (2014) · PubMed · Cited by 24
Hormone Receptors and Epithelial Ovarian Cancer: Recent Advances in Biology and Treatment Options
Borella, F., Fucina, S., Mangherini, L., Cosma, S. D., Carosso, A. R., Cusato, J., Cassoni, P., Bertero, L., Katsaros, D., & Benedetto, C. (2023) · Biomedicines · doi:10.3390/biomedicines11082157 · Cited by 24
Sensitivity to differential NRF1 gene signatures contributes to breast cancer disparities
Ramos, J. D., Yoo, C., Felty, Q. H., Gong, Z., Liuzzi, J. P., Poppiti, R., Thakur, I. S., Goel, R., Vaid, A. K., Komotar, R. J., et al. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03320-9 · Cited by 22
Do CDK4/6 inhibitors have potential as targeted therapeutics for squamous cell cancers?
Kalu, N. N., & Johnson, F. M. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1274731 · Cited by 24
Huang, Y., Wu, H., & Li, X. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01597-x · Cited by 22
Breaking Cancer’s Momentum: CDK4/6 Inhibitors and the Promise of Combination Therapy
Liu, Y., Park, S., & Li, Y. (2025) · Cancers · doi:10.3390/cancers17121941 · Cited by 21
A New Way to Treat Brain Tumors: Targeting Proteins Coded by Microcephaly Genes?
Lang, P. Y., & Gershon, T. R. (2018) · BioEssays · doi:10.1002/bies.201700243 · Cited by 21
Updates on managing advanced breast cancer with palbociclib combination therapy
McShane, T. M., Wolfe, T. A., & Ryan, J. C. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918793849 · Cited by 21
Exploring the Molecular Complexity of Medulloblastoma: Implications for Diagnosis and Treatment
Rechberger, J. S., Toll, S. A., Vanbilloen, W. J. F., Daniels, D. J., & Khatua, S. (2023) · Diagnostics · doi:10.3390/diagnostics13142398 · Cited by 21
Profile of palbociclib in the treatment of metastatic breast cancer
Elbaz, M., & Ehab, M. (2016) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s83146 · Cited by 22
Clinical applications of The Cancer Genome Atlas project (TCGA) for squamous cell lung carcinoma.
Devarakonda, S. H. K., Morgensztern, D., & Govindan, R. (2013) · PubMed · Cited by 21
Mull, B. B., Livingston, J. A., Patel, N. B., Bui, T. N., Hunt, K. K., & Keyomarsi, K. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0707-z · Cited by 21
Zhou, Z., Mutebi, A., Han, S., Bensimon, A. G., Ricculli, M. L., Xie, J., Dalal, A. A., & Culver, K. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2018.1443111 · Cited by 21
Palbociclib—The First of a New Class of Cell Cycle Inhibitors
Schmidt, M., & Sebastian, M. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91442-8_11 · Cited by 20
Cyclin-dependent kinase 4/6 inhibition in cancer therapy
Johnson, N., & Shapiro, G. I. (2012) · Cell Cycle · doi:10.4161/cc.22390 · Cited by 20
Zhang, G., Ma, F.-E., Li, L., Li, J., Li, P., Zeng, S., Sun, H., & Li, E. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.02.017 · Cited by 20
Strategy of combining CDK4/6 inhibitors with other therapies and mechanisms of resistance
Xue, Y., & Zhai, J. (2024) · International Journal of Clinical and Experimental Pathology · doi:10.62347/hgni4903 · Cited by 20
Mutational analysis of breast cancer: Guiding personalized treatments
Ellis, M. J. (2013) · The Breast · doi:10.1016/j.breast.2013.07.003 · Cited by 20
Long, Q., Ma, A., Zhang, H., Cao, Z., Xia, R., Lin, T., Sonpavde, G., White, R. D., Guo, J., & Pan, C.-X. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02609-5 · Cited by 18
Chen, W., Zhang, W., Chen, M., Yang, C., Fang, T., Wang, H., Reid, L. M., & He, Z. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00714-4 · Cited by 17
Emerging Therapies for Breast Cancer
Goel, S., & Chandarlapaty, S. (2022) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041333 · Cited by 17
Synthesis and Clinical Development of Palbociclib: An Overview
Konar, D., Maru, S., Kar, S., & Kumar, K. (2020) · Medicinal Chemistry · doi:10.2174/1573406417666201204161243 · Cited by 17
MAPRE1 promotes cell cycle progression of hepatocellular carcinoma cells by interacting with CDK2
Liang, X.-H., Feng, Z., Liu, F.-Q., Yan, R., Yin, L., Shen, H., & Lu, H. (2020) · Cell Biology International · doi:10.1002/cbin.11442 · Cited by 17
A clinical evaluation of treatments that target cell cycle machinery in breast cancer
Fedele, P., Sanna, V., Fancellu, A., & Cinieri, S. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1672659 · Cited by 16
Xie, N., Qin, T., Ren, W., Yao, H., Yu, Y., & Hong, H. (2020) · Cancer Management and Research · doi:10.2147/cmar.s254365 · Cited by 16
Hong, M. J., Lee, S. Y., Choi, J. E., Jin, C., Kang, H. J., Baek, S. A., Lee, S. Y., Shin, K. M., Jeong, J. Y., Lee, W. K., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7433 · Cited by 16
Increased Expression of Tumor Proliferation Genes in Hispanic Women with Early-Stage Breast Cancer
Kalinsky, K. M., Lim, E. A., Andreopoulou, E., Desai, A. M., Jin, Z., Tu, Y., Hibshoosh, H. H., Wang, A., Greenlee, H., Crew, K. D., et al. (2014) · Cancer Investigation · doi:10.3109/07357907.2014.958232 · Cited by 16
Recent Progress of Cyclin-Dependent Kinase Inhibitors as Potential Anticancer Agents
Li, T., Weng, T., Zuo, M., Wei, Z., Chen, M., & Li, Z. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0129 · Cited by 15
Xu, B., Krie, A. K., De, P. K. R., Williams, C. B., Elsey, R. J., Klein, J., & Leyland-Jones, B. R. (2017) · Cureus · doi:10.7759/cureus.1408 · Cited by 15
Advances in drug development for targeted therapies for glioblastoma
Ge, Y., Wang, Y., Chen, J., Zheng, W., Liu, C., Chen, S., Wang, L., Luo, J., & Li, Z. (2020) · Medicinal Research Reviews · doi:10.1002/med.21676 · Cited by 14
Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells
Blagosklonny, M. V. (2012) · Oncotarget · doi:10.18632/oncotarget.548 · Cited by 14
Onoprienko, A., Bartl, T., Grimm, C., Concin, N., & Polterauer, S. (2024) · Cancers · doi:10.3390/cancers16193268 · Cited by 14
Guo, L., Hu, Y., Chen, X., Li, Q., Wei, B., & Ma, X. (2019) · Cancer Medicine · doi:10.1002/cam4.1970 · Cited by 14
Targeted Therapies for Each Subtype of Breast Cancer
Liu, A., Peng, P., Zhu, Y., Fei, Q., Liu, W., & Zhang, S. (2026) · MedComm · doi:10.1002/mco2.70733 · Cited by 15
Sako, K., Furuichi, K., Makiishi, S., Yamamura, Y., Okumura, T., Le, H. T., Kitajima, S., Toyama, T., Hara, A., Iwata, Y., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.03.022 · Cited by 14
Conditioning neoadjuvant therapies for improved immunotherapy of cancer
Benson, Z., Manjili, S. H., Habibi, M., Guruli, G., Toor, A. A., Payne, K. K., & Manjili, M. H. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.08.007 · Cited by 14
Palbociclib — Taking Breast-Cancer Cells Out of Gear
Carey, L., & Perou, C. M. (2015) · New England Journal of Medicine · doi:10.1056/nejme1506680 · Cited by 14
Self-citationChen, R., Zhou, Z.-L., Meng, X., Lei, Y., Wang, D., & Wang, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1578342 · Cited by 13
Palbociclib - from Bench to Bedside and Beyond
Schmidt, M. (2016) · Breast Care · doi:10.1159/000447001 · Cited by 13
Altered Expression of Cell Cycle Regulators in Adult T-Cell Leukemia/ Lymphoma Patients.
Torshizi, R., Karimiani, E. G., Etminani, K., Akbarin, M. M., Jamialahmadi, K., Shirdel, A., Rahimi, H., Allahyari, A., Golabpour, A., & Rafatpanah, H. (2017) · PubMed Central · Cited by 13
Renal adverse events associated with cyclin-dependent kinase 4/6 inhibitors
Izzedine, H., Wanchoo, R., Sharma, R., & Jhaveri, K. D. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.103060 · Cited by 12
Preclinical discovery and development of abemaciclib used to treat breast cancer
Wright, M. D., & Abraham, J. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1853097 · Cited by 12
Bowles, H., & Clarke, K. (2015) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2015.6.6.6 · Cited by 14
Aslan, M., Aslan, Y., & Levent, A. (2025) · Diamond and Related Materials · doi:10.1016/j.diamond.2025.112001 · Cited by 12
Konova, V., Lagunin, A. A., Pogodin, P. V., Kolotova, E., Shtil, A. A., & Poroikov, V. (2015) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2015.1076516 · Cited by 12
CDK4/6 inhibitors in breast cancer – fromin vitromodels to clinical trials
Saleh, L., Wilson, C., & Holen, I. (2019) · Acta Oncologica · doi:10.1080/0284186x.2019.1684559 · Cited by 11
Banys-Paluchowski, M. J., Krawczyk, N., & Paluchowski, P. (2018) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000511 · Cited by 11
Schreier, A., Munoz-Arcos, L. S., Soto, A. A., Sparano, J. A., & Anampa, J. D. S. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06574-8 · Cited by 11
Fleisher, B., Lezeau, J., Werkman, C., Jacobs, B., & Ait‐Oudhia, S. (2021) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s292161 · Cited by 11
Kostopoulou, O. N., Zupancic, M., Pont, M., Papin, E., Lukoseviciute, M., Agirre, B., Holzhauser, S., & Dalianis, T. (2022) · Viruses · doi:10.3390/v14071372 · Cited by 11
Pediatric diffuse intrinsic pontine glioma: can optimism replace pessimism?
Hargrave, D. R. (2012) · CNS Oncology · doi:10.2217/cns.12.15 · Cited by 11
Reddy, S., Barkhane, Z., Elmadi, J., Kumar, L. S., Pugalenthi, L. S., & Ahmad, M. (2022) · Cureus · doi:10.7759/cureus.23901 · Cited by 10
Xiang, J., Wang, H., Tao, Q., Li, W., Huang, Y., Zhang, Y., Yang, L., & Zhang, S. (2023) · The Journal of Pathology · doi:10.1002/path.6078 · Cited by 10
Morales, F., Ramírez, A., Morata‐Tarifa, C., Navarro-Marchal, S. A., Marchal, J. A., Rosa, J. M. C., & Conejo‐García, A. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0212 · Cited by 10
Franco, J., Balaji, U., Freinkman, E., Witkiewicz, A. K., & Knudsen, E. S. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107793 · Cited by 10
Palbociclib: A breakthrough in breast carcinoma in women
Gupta, A. K., Sharma, S., Dahiya, N., & Brashier, D. B. S. (2016) · Medical Journal Armed Forces India · doi:10.1016/j.mjafi.2015.11.002 · Cited by 9
Scarini, J. F., Lavareze, L., de Lima‐Souza, R. A., Emerick, C., Gonçalves, M. T., Maciel, T. F., Vieira, G. D. S., Kimura, T. D. C., de Sá, R. S., Aquino, I. G., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103863 · Cited by 9
Metadata
- Authors
- Roberts, P. J., Bisi, J. E., Strum, J. C., Combest, A. J., Darr, D. B., Usary, J. E., Zamboni, W. C., Wong, K.-K., Perou, C. M., & Sharpless, N. E.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- ORCID
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-02-01
- Volume
- 104
- Issue
- 6
- Pages
- 476-487
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- PMC
- PMC3309128
- OpenAlex
- W2132726386
- Cited by
- 255
- References
- 79
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 8 · 2023: 10 · 2022: 17 · 2021: 10 · 2020: 26 · 2019: 17 · 2018: 21 · 2017: 25 · 2016: 27 · 2015: 26 · 2014: 25 · 2013: 17 · 2012: 7
- FWCI
- 19.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JNCI Journal of the National Cancer Institute (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- American Cancer Society
- Burroughs Wellcome Fund
- Ellison Medical Foundation
- Golfers Against Cancer
- National Institutes of Health (5r01ag024379-15, ES014635, RO1 P01-ES014635, CA58223, P50-CA58223-09A1)
- National Institute on Aging (R01-AG024379)
- National Cancer Institute (P50‐CA58223‐09A1, R01CA166480, R01CA122794, R01CA140594, UO1-CA141576, R01CA163896, P50CA058223, R01CA148761, P30CA016086, U01CA141576)
- National Institute of Environmental Health Sciences (P01ES014635, R01 P01-ES014635)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- CDK4/6 inhibitors, palbociclib, carboplatin, myelosuppression, hematologic toxicity, retinoblastoma, breast cancer, combination chemotherapy, anticancer activity, cell cycle checkpoints, DNA damage response
- MeSH terms
- Animals, Antineoplastic Combined Chemotherapy Protocols, Blood Platelets, Breast Neoplasms, DNA Damage, DNA, Neoplasm, Doxorubicin, Enzyme Activation, Female, Flow Cytometry, Piperazines, Pyridines, Retinoblastoma, Carboplatin, Apoptosis, Erb-b2 Receptor Tyrosine Kinases, Protective Agents, Caspases, Protein Kinase Inhibitors, Cell Proliferation, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice, G1 Phase Cell Cycle Checkpoints
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.